The mechanism and physiological significance of insulin inactivation and degradation is still incompletely understood. A cytosolic soluble enzyme which rapidly degrades insulin by proteolysis has been found in many animal [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and some human tissues [12] [13] [14] [15] [16] [17] [18] [19] [20] ; reductive disulphide cleavage of insulin, i. e. a glutathione-insulin-transhydrogenase activity, has also been described [11, [20] [21] [22] . Evidence has accumulated that both insulin action and degradation might be mediated through binding of insulin to specific receptors on the plasma cell membrane as the initial step [12, 13, 18, 19, 23, 24] , although the precise nature of this relationship remains to be elucidated. In streptozotocin-diabetic rats, increased insulin degradation by intact muscle has been observed which could be restored to near-normal by insulin treatment [25] . Furthermore, studies in some rare cases of diabetic patients with excessive insulin resistance have suggested that accelerated insulin degradation at the level of target tissues might be a possible alternate explanation for their severe insulin-resistant state [26] [27] [28] [29] [30] [31] .
The present study was designed to investigate aspects of insulin degradation in human diabetes more generally, assaying a specific insulin degrading protease activity from human erythrocytes which has been purlfled recently to homogeneity [14, 15] and shown to exhibit similar properties as a purified enzyme from human skeletal muscle [20] . Type 2 diabetic patients are of particular interest, in whom peripheral insulin resistance due to a combined receptor and post-receptor defect has been implicated in recent years as one pathogenic factor [32] [33] [34] [35] [36] [37] . Insulin degrading enzyme activity (IDEA) and insulin binding to red blood cells in relation to circulating free insulin concentrations were determined in various groups of Type 2 diabetic patients, including some on sulphonylureas, after short-term insulin treatment, and with severe insulin resistance, and compared with normal subjects and with Type 1 diabetic patients.
Subjects and methods

Subjects
Six groups of subjects were studied (Table 1) : 16 healthy control subjects (group 1), 14 well regulated Type I diabetic patients (group 2), 13 well controlled Type 2 diabetic patients on sulphonylurea therapy (who required sulphonylureas in addition to adequate diet for good metabolic control, group 3), nine poorly controlled Type 2 diabetic patients, with secondary failure to diet and sulphonylureas (group 4), Values are given as mean + SEM. a mg glibenclamide or equivalent dose of gliquidone or glibornuride; b p < 0.02 versus all other groups, c p < 0.025 versus groups 1 and 6, d p < 0.025 versus all other groups 11 well controlled Type 2 diabetic patients after 1 week of insulin treatment (most of whom were recruited from the nine Type 2 diabetics previously poorly controlled on sulphonylureas in group4, group 5) and eight (six Type 2, two Type 1) well-controlled patients on insulin, although insensitive to subcutaneously injected insulin as indicated by a daily need of > 80 U, proven in hospital for at least one week (group 6). In this latter group, patients were only included who did not have significant amounts of circulating antibodies, as measured by the method of Dixon [38] .
None (including the control subjects) showed evidence of significant hepatic, renal or infectious disease. Except for mild cardiac insufficiency or hypertension, no other medication was taken by any of the subjects. All subjects had a normal blood count, including normal reticulocyte levels. Informed consent was obtained from all subjects participating in the study and approval was given by the local Ethical Committee.
Me~o~
All subjects were studied in the morning at 8.00 h after an overnight fast. Venous blood was drawn from an antecubital vein into heparinized syringes and processed immediately for estimation of IDEA and insulin binding to erythrocytes. Blood, without anticoagulant, was collected for the determination of total and free serum insulin concentrations [39, 40] and routine chemical profiles, including serum total cholesterol and triglycerides, using a Technicon SMAII autoanalyzer (Technicon, Dublin, Ireland). Capillary blood was taken for glucose determination by the glucose oxidase method and a Beckman glucose analyzer (Beckman Instruments, Clinical Instruments Division, Fullerton, California, USA). Haemoglobin AI concentrations were estimated using pre-packed microcolumns (Boehringer Mannheim, Mannheim, FRG); the normal range of that method being 6.0%-8.5% in our laboratory.
IDEA of erythrocytes was measured by a standard procedure as described previously [1-9, 12-15, 20], using a quenching technique with 5% trichloroacetic acid [14, 15] . The incubation mixture (2 ml) contained Tris/HCl buffer (10mmol/1, pH 7.4), human albumin (1 mg/ml), highly purified pork insulin (100 mU/l, Nordisk, Copenhagen, Denmark), iodoacetamide (1 mmol/1), 125I-insulin as tracer (A14-125I-pork insulin, Novo, Copenhagen, Denmark; spec. act. 211-295 Ci/g), and 0.5 ml haemolysate of erythrocytes washed three times with normal saline and lysed by adding 10 volumes of distilled water. The mixture was incubated in a shaking water bath at 37 ~ for 25 min; 200 lxl aliquots were removed at 0, 5,15, and 25 rain and equal amounts of trichloroacetic acid added. After centrifugation at 10,000 g, duplicate aliquots of the supernatant were counted using a gammacounter (Model NE 1600, Nuclear Enterprises, Edinburgh, UK). The concentration of degraded insulin was calculated from the percentage of radioactivity in the trichloroacetic acid soluble fraction. The time turnover curve was linear over the whole period of measurement and, therefore, initial rates of degrading activity were obtained. Figure 1 shows a typical example. To calculate specific activity, an aliquot of the haemolysate was assayed for the haemoglobin concentration. One unit IDEA was defined as l lxU insulin degraded/min and related to the concentration of haemoglobin of the haemolysate.
Binding of A14-125I-pork insulin to erythrocytes was assayed according to Gambhir et al. [41, 42] . Incubation time was 5 h at 15 ~ Concentration of 125I-insulin in the incubation medium was 4 mU/1. Non-specific binding was measured in the presence of 2.5 x ]0 6 mU/l unlabelled pork insulin. The number of binding sites of erythrocytes (R0-value) was obtained from Scatchard analysis of the insulin bind= ing data [43, 44] , using the amount of the insulin bound (B) and total insulin concentration minus B as the free insulin concentration (F).
Results are given as mean+_SEM. All calculations were performed using a programmable calculator (Compucorp 300, Computer Design Corporation, Los Angeles, California, USA) and the standard statistics package for linear regressions, correlation coefficients and two-tailed Student's t-test.
Results
IDEA of erythrocytes was increased, in comparison with healthy control subjects (group 1), in both groups 
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= 80 of Type 2 diabetic patients on sulphonylureas, as well as in those with good control (group 3) and poor control with secondary failure to diet and oral agents (group 4) (Fig. 2) . In contrast, after I week of insulin treatment resulting in good metabolic control, IDEA became normal in Type 2 diabetic patients, previously poorly controlled on sulphonylureas (group 5), and IDEA was normal in Type 1 diabetic subjects in good metabolic control (group 2). Insulin-treated, yet insulin-insensitive, diabetic patients exhibited the highest IDEA (group 6). Fasting serum concentrations of free insulin were increased in all groups of diabetic subjects (Table 1) , the highest concentrations being found in the insulin-insensitive patients (group 6). The other three groups of Type 2 diabetic patients (groups 3-5) showed remarkably similar fasting insulin levels, including the group with secondary failure to oral therapy (group 4) and the well compensated patients recently changed to insulin treatment (group 5).
Competition curves of insulin binding to erythrocytes are presented in Figure 3A . Maximal specific insulin binding of the poorly controlled Type 2 diabetic patients on sulphonylureas was significantly lower compared with normal subjects (p < 0.01), with well regu- In contrast, in the Type 2 diabetic patients, significant inverse associations between fasting insulin concentrations and IDEA were apparent (Fig.4) , especially in group 4 who had secondary failure to sulphonylurea treatment (y = -1.72x+126.54; r---0.72; p <0.05) and in group 5 who had 1 week of insulin treatment (y = -3.36x+ 135.96; r= -0.84;p < 0.01), i.e. the lower the serum insulin, the higher the IDEA and vice versa.
Discussion
Although increased insulin degradation has been recognized for many years as a theoretical cause of an impaired response to insulin, only recently have a few diabetic patients been described with extreme resistance to subcutaneous insulin and markedly elevated insulin degrading activity of adipose or muscle tissue [26] [27] [28] [29] [30] [31] . The present study now demonstrates more generally elevated and fluctuating IDEA of erythrocytes in a variety of subgroups of patients with Type 2 diabetes. IDEA, purified to homogeneity, has been characterized recently as a sulphydryl-dependent protease, which specifically degrades insulin at physiological hormone concentrations into peptides smaller than the A-chain of insulin and can be inhibited by several protease inhibitors [14, 15] . Though red blood cells are not a known target tissue of insulin action, they do carry insulin receptors, and erythrocyte IDEA appears to show properties similar to the insulin degrading proteases of insulinsensitive tissues from animal sources [1] [2] [3] [4] [5] 10] and especially similar to the enzyme purified from human skeletal muscle [20] .
Erythrocyte IDEA as measured here does not contain glutathione-induced-transhydrogenase activity, nor is it affected by free sulphydryl compounds present in the haemolysate, since 1 mmol/1 iodoacetamide was added to the assay mixture [14] . In addition, a sex-or age-dependency of human erythrocyte IDEA has been excluded by measurements in 169 normal subjects [45] . In the context of the trichloroacetic acid method used for the determination of IDEA, it should also be pointed out that the split products of usI-insulin, as found by Sephadex chromatography, have been shown previously to be trichloroacetic-acid soluble and the conversion of t25I-insulin to these products to be complete [14] [15] . Even if it cannot be ruled out that the trichloroacetic acid method underestimates the degradation of insulin in that the initial split material might be indistinguishable from insulin when Sephadex chromatography is applied [20] , this should not interfere with the outcome of the present study since actual rates of increasing trichloroacetic acid soluble products have been determined for the estimation of IDEA.
The present data showed normal IDEA in reasonably well controlled Type 1 diabetic patients (Fig. 2) . In contrast, well controlled Type 2 diabetic patients on diet and sulphonylureas showed increased IDEA, as did the Type 2 diabetics with secondary failure to diet and oral agents. Treatment of such patients with insulin for 1 week and thus achieving good metabolic control, resulted in IDEA becoming normal. Erythrocyte IDEA was highest, however, in patients with obvious insensitivity to subcutaneously injected insulin, as indicated by a daily insulin dose of more than 80 U, whose insulin resistance could not be attributed to increased circulating insulin antibodies. Furthermore, the present study has accumulated some indirect correlative evidence for a connection between red blood cell IDEA and both fasting insulin concentrations and maximal specific insulin binding to the erythrocyte receptor, particularly in normal subjects. In the Type 2 diabetic patients, however, the correlation of serum insulin levels with IDEA was not direct, but inverse (Fig. 4) . These observations appear to agree with findings in the literature, where increased insulin degradation has been described in muscle from insulin-deficient, streptozotocin-diabetic rats, while insulin binding to muscle was increased at the same time, a phenomenon which reverted to normal after one week of insulin treatment [25] . An association of basal plasma insulin values with insulin degrading activities of muscle and fat tissue has also been shown in a previous study in some non-diabetic and diabetic insulin-resistant subjects [27] . These data have been interpreted as suggesting that insulin degrading enzymes are inducible and thereby influencing insulin metabolism or action respectively, with increased insulin degradation going along with a state of both insulin deficiency and insulin resistance [20, 25, 27] .
Erythrocyte IDEA as reported here is an in vitro phenomenon and may not necessarily reflect the condition in vivo, particularly in insulin target tissues. However, the results seem to warrant subsequent work to substantiate whether increased insulin degradation by insulin-sensitive tissues in vivo is indeed a common feature of Type 2 diabetes and might be involved in the process of peripheral insulin resistance in such patients. This might be of particular importance in view of the now widely accepted notion of post-receptor defects being the predominant origin of insulin resistance in Type 2 diabetes, and not receptor abnormalities [32] [33] [34] [35] [36] [37] , and that intensive insulin treatment seems to be able to ameliorate considerably post-receptor defects, e.g. in insulin-stimulated glucose disposal [35] . It is of great interest that recent evidence has been obtained that the plasma clearance rate of insulin may vary in diabetes [46] [47] [48] , with insulin treatment for 1 week returning increased clearance to normal [46] , and that there seems to be a close association between insulin clearance, insulin binding and insulin sensitivity [47, 48] .
